TRT Side Effects: Fertility, Blood Counts, Prostate and Heart: What Men Should Know Before Starting

The man in the waiting room had done his homework. He had a screenshot of a hormone panel from a telehealth app, a podcast clip on his phone, and one question written on the back of a parking ticket: Is this going to wreck my heart? He is not alone. Prescriptions for testosterone have roughly doubled in the United States over the past decade, and search interest in trt side effects has climbed alongside them.

Two things pushed the topic into the spotlight. In 2025 the FDA asked manufacturers to remove the class-wide boxed warning about cardiovascular risk from testosterone products, citing the TRAVERSE trial, while keeping a newer warning about blood pressure. At the same time, social feeds filled with men in their 30s describing testosterone as a wellness upgrade rather than a treatment for a diagnosed deficiency.

As of early 2026, the honest picture sits between the alarm of 2015 and the enthusiasm of the algorithm. This piece walks through what the evidence shows about fertility, blood counts, the prostate and the heart, and how strong each piece of that evidence is.

What changed recently with TRT side effects

For a decade, every testosterone product in the United States carried a boxed warning about a possible increase in heart attacks and strokes. That warning dated from 2015 and rested on observational studies and one small trial in frail older men that was stopped early. It was a precaution, not a verdict.

The verdict arrived in June 2023. The TRAVERSE trial, published in the New England Journal of Medicine, randomized 5,246 men aged 45 to 80 with low testosterone and existing heart disease or high cardiovascular risk to either a daily testosterone gel or an identical placebo gel. After a mean follow-up of about 33 months, major cardiac events occurred in 7.0 percent of the testosterone group and 7.3 percent of the placebo group. Statistically, the two arms were indistinguishable on the primary outcome.

The same trial produced less comfortable numbers in its secondary analyses. Atrial fibrillation, an irregular heart rhythm that raises stroke risk, occurred in 3.5 percent of men on testosterone versus 2.4 percent on placebo. Acute kidney injury and pulmonary embolism, a clot lodged in the lung, were also more frequent in the treated group. A 2024 follow-up paper reported more clinical fractures among men on testosterone, roughly 3.5 percent compared with 2.5 percent, a finding that surprised the investigators because testosterone was expected to strengthen bone.

In February 2025 the FDA responded by requesting label changes across the class: the cardiovascular boxed warning came off, and a warning about increased blood pressure, based on ambulatory monitoring studies, stayed on. That is the regulatory backdrop to the current surge in interest. It is also why a careful reader should resist headlines in either direction. The heart-attack fear softened; the rhythm, clot and fracture signals did not disappear.

Why trt side effects start with what testosterone therapy actually does

Testosterone replacement therapy, or TRT, means giving a man pharmaceutical testosterone because his own testes do not make enough. Hypogonadism is the medical term for that shortfall, and it is diagnosed with symptoms plus at least two morning blood tests below the laboratory reference range, not with a single afternoon reading or a symptom quiz.

Almost every side effect on the list follows from three facts about the hormone. First, testosterone is a growth signal. It tells the bone marrow to make more red blood cells, tells oil glands to work harder and tells prostate tissue to stay active. Second, a portion of any testosterone in the body is converted to estradiol, the main estrogen, by an enzyme called aromatase. That conversion is normal and even protective for bone, but in excess it can cause breast tenderness and fluid retention. Third, the brain reads circulating testosterone as a signal to stand down. The pituitary gland stops releasing the two messenger hormones, LH and FSH, that instruct the testes to produce both testosterone and sperm.

That third mechanism explains the paradox that trips up so many men: taking testosterone lowers your own testosterone and can shut down sperm production almost completely. It is not a rare idiosyncrasy. It is the drug working exactly as pharmacology predicts.

The size of each effect depends on how high blood levels climb and how much they swing. A steady level in the middle of the normal range behaves very differently from peaks well above it followed by troughs below. Formulation, individual metabolism and pre-existing conditions such as sleep apnea or a high baseline red cell count all shape which of these effects a given man notices. Understanding that framework makes the rest of this article far less mysterious.

How testosterone therapy affects fertility, and how long recovery takes

Fertility is the side effect men most often learn about after the fact. Because external testosterone suppresses LH and FSH, the testes stop receiving the signal to make sperm. Within a few months, sperm counts in most men on TRT fall to very low or undetectable levels. This is so reliable that testosterone has been studied as a male contraceptive.

The best recovery data come from a pooled analysis of those contraceptive trials, published in the Lancet in 2006 and indexed in PubMed. Among more than 1,500 men who had used testosterone-based regimens, about two-thirds regained a sperm count of 20 million per milliliter within 6 months of stopping, roughly 90 percent within 12 months, and nearly all within 24 months. Older age, longer duration of use and a lower starting count predicted slower recovery. These men were healthy volunteers, so recovery in men with underlying testicular problems may be slower or incomplete.

Two practical points follow. A man who wants children in the next few years should raise that with his clinician before the first prescription, not after. Guidelines from the Endocrine Society and the American Urological Association both list a desire for near-term fertility as a reason to consider alternatives to standard testosterone. Second, banking sperm before starting is an option some clinicians discuss, and the decision belongs in that conversation.

Testicular shrinkage, called testicular atrophy, is the visible cousin of this process. Without LH stimulation, the testes reduce in volume, sometimes noticeably. It is usually reversible when the hormone is withdrawn under supervision, though the timeline mirrors sperm recovery rather than days or weeks.

The evidence here is strong: it comes from randomized contraceptive trials and consistent physiology. Of all the trt side effects, this is the one with the least uncertainty and the most regret attached when it is a surprise.

TRT and blood counts: why hematocrit is the number your doctor watches

Hematocrit is the percentage of your blood volume made up of red blood cells; a typical adult male value sits in the low to mid 40s. Testosterone stimulates the kidney hormone erythropoietin and suppresses hepcidin, a protein that limits iron availability, so the marrow produces more red cells. A modest rise is expected. A large one is the single most common laboratory reason clinicians pause or adjust therapy.

When hematocrit climbs above about 54 percent, the threshold cited in Endocrine Society guidance, blood becomes thicker and more viscous. Observational data associate that state, called erythrocytosis or secondary polycythemia, with a higher risk of clots, including stroke and venous thromboembolism. The absolute risk for an individual man is uncertain, but the mechanism is plausible and the guideline response is consistent: recheck, look for other causes such as sleep apnea or smoking, and let the prescribing clinician decide on next steps.

Formulation matters a great deal. Short-acting intramuscular injections create peaks well above the normal range in the days after each shot, and observational series report erythrocytosis in a substantial minority of men using them. Transdermal gels and patches, which deliver steadier levels, are associated with considerably lower rates. Long-acting injections and nasal gel fall somewhere between. This is one reason many specialists steer men with a high baseline hematocrit, or a history of clots, away from the peak-and-trough pattern.

Monitoring is straightforward and cheap in medical terms: a complete blood count before starting, again at three to six months, then at least yearly. Men should expect these checks and ask about them if they are not offered. A telehealth prescription without lab follow-up leaves this risk unwatched.

Symptoms of a high red cell count are vague when they appear at all: headaches, facial flushing, dizziness, a ruddy complexion. That is precisely why the blood test, not the mirror, is the safeguard.

Does TRT cause prostate cancer? What PSA changes really mean

The fear that testosterone feeds prostate cancer is older than most of the men asking about it. It traces to 1941, when researchers showed that castration shrank advanced prostate tumors. If removing testosterone helps, the reasoning went, adding it must harm.

Modern evidence has complicated that logic. Prostate tissue appears to have a saturation point: once androgen receptors are occupied at relatively low testosterone levels, additional hormone does not drive further growth. In TRAVERSE, high-grade prostate cancer was diagnosed in 0.19 percent of men on testosterone and 0.12 percent on placebo over roughly three years, a difference that did not reach statistical significance. Earlier meta-analyses of smaller trials found no increase in prostate cancer incidence either.

That is reassuring but not final. Three years is short in prostate cancer terms, trial participants were screened to exclude men with suspicious findings, and no trial has been designed with prostate cancer as its primary outcome. The fair summary, as the Harvard Health and Mayo Clinic reviews put it, is that current evidence does not show TRT causes prostate cancer, while the possibility of accelerating an existing undiagnosed tumor cannot be fully excluded.

PSA, prostate-specific antigen, is a protein made by prostate cells and measured in blood as a screening marker. Testosterone typically nudges PSA upward by a small amount in the first year, particularly in men whose starting levels were low. Guidelines recommend a baseline PSA and digital rectal examination for men over 40 before starting, a repeat PSA at three to twelve months, and referral to a urologist if the rise exceeds a defined threshold or a nodule is felt. Known prostate cancer, and in many guidelines an unevaluated elevated PSA, remain reasons not to prescribe.

Benign prostatic enlargement is a separate question. Some men notice more urinary urgency or a weaker stream on therapy; trials have not shown a consistent worsening of symptom scores, but individual reports are common enough that clinicians ask.

TRT and your heart: what TRAVERSE settled and what it did not

Between 2010 and 2015, several observational studies and one halted trial suggested that testosterone increased heart attacks, especially in older men. Others found the opposite, that low testosterone itself predicted cardiovascular death. Neither type of study can prove cause and effect, which is why the FDA demanded a large randomized trial as a condition of continued marketing.

TRAVERSE was that trial, and its design deserves respect. Every participant already had cardiovascular disease or at least three risk factors, making it a high-risk population where any harm should have shown up. The primary outcome, a composite of cardiovascular death, non-fatal heart attack and non-fatal stroke, was almost identical in the two arms. On that specific question, the evidence is now strong: testosterone gel that keeps levels in the normal range did not increase heart attacks or strokes over about three years.

The limitations matter just as much. The trial tested a gel, not injections, so the peak-and-trough pattern that raises hematocrit was not studied. Average testosterone levels achieved were in the lower half of the normal range; supraphysiologic levels were never tested. Follow-up was around three years, not the ten or twenty years many men envision. And a large share of participants stopped the gel before the trial ended, which can blur differences.

Then there are the secondary signals. Atrial fibrillation, acute kidney injury and pulmonary embolism were all more common with testosterone. Because these were among many secondary outcomes, some could be chance findings, but they align with the known effects of testosterone on fluid balance and blood thickness. The American Heart Association continues to advise that testosterone should not be used to prevent heart disease and should be prescribed only for documented deficiency.

The heart story, then, is not closed. It has moved from alarm about the biggest outcomes to attention on the subtler ones.

Blood pressure, fluid retention and blood clots: the quieter cardiovascular risks

Heart attacks make headlines. Three less dramatic effects deserve equal attention because they are common, measurable and often overlooked.

Blood pressure first. When oral testosterone products were studied with 24-hour ambulatory monitoring, systolic pressure rose by an average of several millimeters of mercury after four months. That sounds trivial, but across a population a rise of that size translates into a meaningful increase in stroke and heart failure events over years. The finding was strong enough that the FDA kept a blood pressure warning on testosterone labeling even as it removed the boxed cardiovascular warning in 2025. Home or clinic blood pressure checks are now a routine part of monitoring, and men with poorly controlled hypertension are usually asked to address that before starting.

Fluid retention is the likely mechanism behind both the blood pressure change and the ankle swelling some men report. Testosterone promotes sodium and water retention by the kidneys. In men with heart failure or kidney disease, this can tip a fragile balance, which is why severe uncontrolled heart failure is a listed reason to avoid therapy. The acute kidney injury signal in TRAVERSE may be related, though its cause is not established.

Venous thromboembolism, a clot in a deep vein that can travel to the lungs, carries its own labeling warning since 2014. Case reports and registry data linked testosterone to clots, particularly in men with an inherited clotting tendency or a very high hematocrit. TRAVERSE found pulmonary embolism in 0.9 percent of treated men versus 0.5 percent on placebo. In absolute terms that is roughly four additional clots per thousand men over three years, small for an individual and meaningful across a population.

None of these effects should be framed as reasons for panic. They are reasons for a blood pressure cuff, a hematocrit check and a frank conversation about personal history before the first prescription.

Does TRT cause depression or mood swings?

Men arrive at this question from two directions. Some hope testosterone will lift a low mood; others have read that it causes rage or depression. The evidence supports neither extreme.

Low testosterone is associated with depressive symptoms in observational studies, but association is not cause: obesity, poor sleep, chronic illness and depression itself all lower testosterone. When randomized trials have tested testosterone against placebo in men with confirmed deficiency, results are mixed. A 2019 meta-analysis in JAMA Psychiatry, indexed in PubMed, pooled 27 trials and found a small to moderate reduction in depressive symptoms, with the effect larger in men whose baseline symptoms were mild and whose levels were clearly low. Trials in men with major depression and normal testosterone have generally shown no benefit. The Endocrine Society does not recommend testosterone as a treatment for depression, and any such use would be off-label, a decision that rests with the treating clinician.

Can it worsen mood? Irritability, anxiety and mood swings are reported, most often in two situations. The first is supraphysiologic dosing, where levels exceed the normal range; studies of anabolic steroid misuse at very high levels document aggression and, on withdrawal, depression. The second is the trough period with short-acting injections, when levels dip below normal and energy and mood dip with them. Men who describe feeling great for days then flat for days are often describing pharmacokinetics, not personality.

Sleep disruption adds another layer. Testosterone can worsen obstructive sleep apnea, and untreated apnea is one of the most reliable drivers of low mood and irritability. A man who feels worse on therapy deserves a sleep history, not just a hormone recheck.

The evidence grade here is moderate for a small mood benefit in truly deficient men and low for a direct causal link to depression. New or worsening depression on therapy should always prompt a call to the prescriber.

Skin, breasts, sleep and testicles: the everyday side effects of testosterone therapy

The side effects men actually notice week to week rarely appear in cardiology journals. They are dermatological, cosmetic and nocturnal, and they drive many decisions to stop.

Acne and oily skin top the list. Androgens stimulate sebaceous glands, so breakouts on the back, shoulders and chest are common in the first months, particularly with formulations that produce high peaks. Most cases are mild and settle; a minority need dermatology input. Male-pattern hair loss can accelerate in men already genetically prone to it, because testosterone is converted in the scalp to dihydrotestosterone, the hormone that miniaturizes follicles.

Gynecomastia, the enlargement of male breast tissue, follows from aromatization to estradiol. Tenderness or a small firm area behind the nipple is the usual presentation. It is more common in men with higher body fat, since fat tissue contains more aromatase. Any breast lump in a man should be examined rather than assumed to be a side effect.

Sleep apnea deserves special mention. Testosterone appears to alter the muscle tone of the upper airway and the brain’s breathing drive during sleep, and it can unmask or worsen obstructive apnea. Untreated severe apnea is listed as a reason to postpone therapy. Partners often notice louder snoring or pauses in breathing before the man does.

Formulation-specific nuisances round out the picture. Gels can transfer to a partner or child through skin contact, and the labeling carries a warning about secondary exposure causing early puberty signs in children; washing hands and covering the site are standard advice. Patches cause skin irritation in a notable share of users. Injections can cause site pain, and a rare but frightening coughing fit, called pulmonary oil microembolism, has been reported with some oil-based products. Pellets implanted under the skin can extrude or cause infection. Nasal gel causes nasal irritation and, in some men, a runny nose.

None of these is dangerous in most cases. All of them are worth reporting, because they often signal levels running higher than intended.

Long-term side effects of TRT: what we know after five years and beyond

Here honesty requires admitting the size of the gap. The longest randomized trial, TRAVERSE, followed men for a mean of under three years. Every claim about decade-long safety, positive or negative, rests on observational data, registry studies and extrapolation from physiology.

What observational data suggest is modestly reassuring on the biggest fears. Registry studies from several countries following men for five to ten years have not shown a consistent increase in prostate cancer or overall mortality among treated men; some show lower mortality, which is more likely to reflect healthier men being prescribed the drug than a protective effect. These studies cannot separate the two, which is the central limitation of all observational evidence.

Bone is where the long view turned unexpectedly. Testosterone increases bone mineral density in deficient men, and everyone assumed fewer fractures would follow. TRAVERSE found the opposite: more clinical fractures in the testosterone group over three years. The investigators speculated that increased energy and activity led to more falls, but the mechanism is unknown. Whether this persists beyond three years is unstudied.

The hypothalamic-pituitary-gonadal axis, the hormonal chain from brain to testes, becomes a long-term consideration in its own right. The longer a man’s natural production is suppressed, the longer recovery tends to take if he stops, and in some men, particularly older ones or those with an underlying testicular problem, it may not fully return. This is reversible in most cases but not guaranteed.

Erythrocytosis, blood pressure and sleep apnea are cumulative concerns rather than early ones; their harm, if any, accrues over years of exposure, which is why monitoring does not end after the first twelve months.

The evidence grade for long-term safety is low, in the formal sense: it comes from observational data and expert opinion. A man starting in his 30s should understand that he is, in effect, part of an uncontrolled experiment that no trial has yet run.

How much TRT is too much? Supraphysiologic levels explained

The question usually means something specific: how do I know if my dose is excessive? The clinical answer is not a milligram figure but a blood level. Guidelines aim to bring total testosterone into the middle of the normal reference range for healthy young men and to keep it there. Levels above the top of that range are called supraphysiologic, and that is where the risk profile changes shape.

Above the normal range, the dose-response for harm steepens. Hematocrit rises more sharply. Blood pressure climbs. Estradiol rises in parallel, bringing breast tenderness and fluid retention. Sleep apnea worsens. Mood effects, including irritability and, in extreme cases, aggression, become more likely; these are well documented in studies of anabolic steroid misuse at levels several times the physiological ceiling. The heart, too, appears less forgiving: cardiac imaging studies of long-term high-dose users have found reduced pumping function and thickened heart muscle, though those men were taking far more than any therapeutic regimen.

Timing of the blood test matters as much as the result. With short-acting injections, a level drawn two days after a shot can look excessive while a level drawn just before the next one looks deficient. Clinicians interpret the number against the formulation and the timing; men comparing screenshots online usually are not.

Symptoms are not a reliable dose gauge. Feeling energetic does not mean the level is right, and many men feel best at levels that are quietly pushing their hematocrit toward the threshold. That mismatch is the most common way therapy drifts into excess.

The decision about whether a level is too high, and what to do about it, belongs to the prescribing clinician, informed by labs drawn at the correct time. Adjusting a dose on the basis of a forum post or a friend’s protocol is exactly the behavior that turns a monitored treatment into an unmonitored risk.

Is it safe to stop TRT cold turkey?

Stopping abruptly will not cause a medical emergency in the way that stopping some heart or seizure medicines can. It will, however, produce a predictable and often miserable gap, and doing it without medical input forfeits the chance to manage that gap.

The physiology is simple. While on therapy, the pituitary has been silent. When external testosterone is withdrawn, blood levels fall within days for gels and within weeks for long-acting injections, but the pituitary does not immediately resume sending LH and FSH. For a period ranging from weeks to many months, a man can have lower testosterone than before he started. Fatigue, low libido, erectile difficulty, poor concentration, low mood and loss of muscle fullness are typical in that window. Some men describe it as the original symptoms returning with interest.

Recovery time depends on how long therapy lasted, age, and whether the testes were functioning normally beforehand. Data from contraceptive trials show most men regain normal production within a year, but men with primary testicular disease may not recover because the deficiency was never pituitary in origin. Anyone with a history of depression should be especially cautious, since the withdrawal trough can deepen low mood.

Clinicians have options during this period that are not available to a man stopping alone. Some monitor levels and symptoms; some use medicines that stimulate the pituitary to restart production, an approach with limited trial evidence that sits with the treating specialist. What matters is that the plan is supervised.

Men stop for good reasons: a desire for children, a side effect, a change of mind. Each is legitimate. The advice from every mainstream source, including the Mayo Clinic and Cleveland Clinic, is the same: do not stop or change the regimen on your own. Tell the prescriber, agree a plan, and arrange follow-up blood tests so that recovery, or the lack of it, is documented rather than guessed.

TRT side effects by formulation: gel, injection, patch, pellet, nasal and oral

Not all testosterone behaves the same way in the body. The route of delivery shapes how steady blood levels are, and steadiness is the variable behind most of the differences below. This summary reflects labeling, guideline reviews and observational comparisons; head-to-head randomized data between formulations are limited.

Formulation	Level pattern	Side effects more likely with this route	Notes
Transdermal gel	Steady, daily	Skin irritation; transfer to partner or child via contact	Formulation tested in TRAVERSE; lowest erythrocytosis rates
Short-acting intramuscular injection	High peak, low trough	Erythrocytosis; mood and energy swings; injection site pain	Peak levels often exceed normal range briefly
Long-acting intramuscular injection	Steadier over weeks	Erythrocytosis (less than short-acting); rare pulmonary oil microembolism cough reaction	Administered in a clinical setting under a safety program
Transdermal patch	Steady	Skin redness and itching, frequently leading to discontinuation	No transfer risk
Subcutaneous pellet	Steady for months, then declining	Extrusion; infection at implant site; difficult to adjust once placed	Requires a minor procedure
Nasal gel	Short-acting, multiple daily	Nasal irritation, runny nose, nosebleeds	May suppress sperm less, based on small studies
Oral undecanoate capsule	Twice daily, food-dependent	Blood pressure increase documented on ambulatory monitoring	Carries a specific blood pressure warning

Two patterns stand out. Anything that produces high peaks pushes hematocrit and mood swings; anything absorbed through skin carries a local skin cost and, for gels, a transfer risk to others. The oral route is the one with the clearest blood pressure signal, which is why home monitoring is emphasized there.

Choosing among these is not a consumer decision made from a table. It depends on baseline hematocrit, blood pressure, skin, household composition, fertility plans and how a man’s body handles each. The table is a guide to the questions worth asking, and the prescribing clinician is the person to ask.

What the evidence actually says about trt side effects, graded

Medical evidence comes in tiers. Randomized controlled trials, where men are assigned by chance to treatment or placebo, are the strongest because they cancel out the differences between people who choose treatment and those who do not. Observational studies, which follow men who happened to be treated, can show associations but not causes. Expert opinion and physiological reasoning fill the gaps. Here is where each major claim stands.

Strong evidence, from randomized trials. Suppression of sperm production and its gradual recovery after stopping. No increase in heart attack or stroke over about three years with a gel in high-risk men. A modest increase in atrial fibrillation, pulmonary embolism, acute kidney injury and fracture in the same trial, though these were secondary outcomes and carry more uncertainty than the primary. A blood pressure rise with oral formulations, measured by ambulatory monitoring.

Moderate evidence, from smaller trials and consistent observational data. Increased hematocrit, with higher rates for injections than gels. A small PSA rise in the first year without an increase in detected prostate cancer over three years. A small improvement in depressive symptoms in men with confirmed deficiency. Worsening of obstructive sleep apnea.

Low evidence, from observational data and case series. Long-term prostate cancer risk beyond three years. Long-term mortality effects in either direction. Whether the fracture signal persists. The safety of injections, which no large cardiovascular outcome trial has tested. Mood effects at therapeutic levels beyond the trough phenomenon.

Physiological reasoning and expert opinion. Almost everything about men under 40 without a diagnosed deficiency, because trials excluded them. Everything about levels above the normal range in a medical context, because no ethical trial can test that.

The pattern is instructive. The best-studied risks are moderate in size and manageable with monitoring. The least-studied are exactly the situations most heavily promoted online: young men, high levels, indefinite duration. That inversion, not any single number, is the most important thing the evidence says.

Common myths about TRT side effects, corrected

Viral claims about testosterone tend to be half right, which makes them harder to dismiss than outright fiction. Five of the most persistent deserve a direct answer.

Myth: TRAVERSE proved testosterone is safe for the heart. It showed no increase in heart attacks and strokes over about three years with a gel kept in the normal range. It also found more atrial fibrillation and pulmonary embolism. It did not study injections, high levels or long durations. “Not proven harmful on one outcome” is not the same as “proven safe.”

Myth: Testosterone causes prostate cancer. Randomized and observational data have not shown an increase in incidence. What remains true is that testosterone can accelerate an existing prostate cancer, which is why men with known cancer are not treated and why PSA monitoring continues.

Myth: Fertility comes back as soon as you stop. Recovery takes months, commonly six to twelve, and occasionally two years or longer. A minority of men, especially older ones or those with testicular disease, do not fully recover.

Myth: If your level is in range, you cannot have side effects. Hematocrit, blood pressure and sleep apnea can all worsen at levels within the normal range, particularly with peak-and-trough delivery. The lab value is necessary, not sufficient.

Myth: Low testosterone is normal aging and treating it is anti-aging medicine. Testosterone does decline gradually with age, by roughly one percent a year after 30 according to Mayo Clinic and Harvard Health reviews, but most older men remain within the normal range. Guidelines reserve treatment for men with symptoms and confirmed low levels on repeat morning testing. Trials of testosterone in older men with borderline levels have shown small effects on sexual function and walking distance, not restored youth.

A sixth claim circulates about compounded or research-grade testosterone products sold online without a prescription. These are unapproved for sale to consumers, their content and sterility are unverified, and they are not for self-use under any circumstances.

When to see a doctor about TRT side effects

Every man on testosterone therapy should have a clinician who ordered it, is monitoring it and can be reached. The schedule below reflects mainstream guideline practice: a baseline assessment including testosterone, hematocrit, PSA for men over 40, blood pressure and a sleep and fertility history; repeat testosterone and hematocrit at three to six months; PSA within the first year; then at least annual review. If a prescriber has not offered these checks, that absence is itself a reason to seek a second opinion from a licensed physician.

Some symptoms should not wait for the next appointment. Seek urgent medical attention for any of the following:

• Sudden chest pain, pressure or shortness of breath, which could indicate a heart attack or a clot in the lung
• Sudden weakness on one side, facial drooping, slurred speech or vision loss, the warning signs of stroke
• Pain, warmth or swelling in one calf or thigh, suggesting a deep vein clot
• A racing, fluttering or irregular heartbeat, especially if new or accompanied by dizziness
• Coughing fits, throat tightness or difficulty breathing in the minutes after an injection
• Thoughts of self-harm or a marked, sustained drop in mood

Contact the prescribing clinician promptly, within days rather than months, for persistent headaches or facial flushing, a new breast lump or tenderness, a partner reporting loud snoring or breathing pauses, difficulty urinating or blood in the urine, ankle swelling, a marked rise in home blood pressure readings, new acne severe enough to scar, or any pain, redness or discharge at an injection, pellet or patch site. A child or partner who develops signs of unexpected hormone exposure after contact with a gel user also needs medical assessment.

Men who are considering stopping, want to plan a pregnancy, are scheduled for surgery, or have been diagnosed with a new condition such as heart failure, kidney disease or sleep apnea should raise it with the prescriber before making any change themselves.

Nothing in this article replaces that conversation. It exists to make it a better one.

Frequently asked questions

Does TRT have long-term side effects?

The longest randomized trial followed men for under three years, so long-term safety beyond that rests on observational data and physiology. Known cumulative concerns include raised hematocrit, higher blood pressure, worsened sleep apnea and prolonged suppression of the body’s own testosterone and sperm production. Registry studies over five to ten years have not shown a consistent rise in prostate cancer or mortality, but they cannot prove safety. Ongoing monitoring is the practical answer to that uncertainty.

Is it safe to stop TRT cold turkey?

Stopping abruptly is not life-threatening, but it usually produces weeks to months of fatigue, low libido, poor mood and erectile difficulty while the pituitary slowly restarts natural production. Recovery can take longer in older men or after years of use, and in some men it is incomplete. Mainstream guidance is to tell the prescribing clinician first, agree a supervised plan and arrange follow-up blood tests rather than stopping alone.

How much TRT is too much?

Clinicians judge this by blood level, not by a number of milligrams. Guidelines aim for total testosterone in the middle of the normal range for healthy young men, drawn at the correct time for the formulation. Levels above the top of that range are supraphysiologic and carry sharper rises in hematocrit, blood pressure, estradiol and mood effects. Feeling energetic is not a reliable gauge; only correctly timed labs interpreted by the prescriber are.

Can TRT increase depression?

Direct evidence that therapeutic testosterone causes depression is weak. Pooled trials in men with confirmed deficiency show a small average improvement in depressive symptoms. Low mood on therapy is most often reported during the trough phase of short-acting injections, at supraphysiologic levels, or when sleep apnea has worsened. New or deepening depression while on treatment should be reported to the prescriber promptly rather than waited out.

What are the long-term side effects of TRT on fertility?

External testosterone suppresses the pituitary signals that drive sperm production, and counts typically fall to very low or undetectable levels within months. Most men recover within a year of stopping under supervision, but longer use, older age and pre-existing testicular problems slow recovery, and a minority do not fully regain their previous counts. Men planning children should raise this before starting, when sperm banking and alternative approaches can be discussed.

Does testosterone therapy affect fertility even at low doses?

Yes. Suppression of sperm production depends on the brain sensing enough circulating testosterone to stop releasing LH and FSH, and levels within the normal treatment range are sufficient to do that in most men. Lower levels may suppress somewhat less completely, and small studies suggest the nasal gel may spare sperm production more than other routes, but no standard testosterone regimen should be considered fertility-safe.

Does TRT raise your risk of blood clots?

Testosterone labeling has carried a venous clot warning since 2014, and the TRAVERSE trial found pulmonary embolism in 0.9 percent of treated men versus 0.5 percent on placebo. The likely mechanisms are a higher red blood cell count and effects on clotting factors. Men with a personal or family history of clots, or a high baseline hematocrit, are generally assessed more carefully, and calf swelling or sudden breathlessness on therapy needs urgent evaluation.

Does TRT cause hair loss or acne?

Both are common, particularly in the first months and with formulations that produce high peaks. Testosterone stimulates oil glands, so acne on the back, chest and shoulders is frequent and usually settles. In men genetically prone to male-pattern baldness, conversion of testosterone to dihydrotestosterone in the scalp can speed hair thinning. Neither is dangerous, but persistent or scarring acne is worth discussing with the prescriber or a dermatologist.

Why does my doctor keep checking my hematocrit on TRT?

Testosterone tells the bone marrow to make more red blood cells, and a hematocrit rising above roughly 54 percent thickens the blood and is associated with higher clot and stroke risk in observational data. It is the most common laboratory reason therapy is paused or adjusted. Guidelines call for a check before starting, again at three to six months, then at least yearly, with more frequent checks for men using injections.

Does TRT worsen sleep apnea?

It can. Testosterone appears to alter upper airway muscle tone and the brain’s breathing drive during sleep, and it may unmask or worsen obstructive sleep apnea, especially in men who are overweight or already snore heavily. Severe untreated apnea is a listed reason to postpone therapy. A partner noticing louder snoring or pauses in breathing after starting should prompt a conversation with the prescriber and, often, a sleep study.

References

• NIH PMC: Risks of testosterone replacement therapy in men
• MedlinePlus: Testosterone Injection
• Cleveland Clinic: Low Testosterone (Male Hypogonadism)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.